|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/25/12 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 168.32Cr 5.19Cr 4.56Cr 4.26Cr 3.91Cr 7.32Cr 497.54Cr 7.5Cr 51Cr 20Cr 246.21Cr 20Cr 19Cr 851.13Cr | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 197.21Cr 6.09Cr 5.35Cr 4.99Cr 4.58Cr 8.58Cr 582.94Cr 8.79Cr 59Cr 23Cr 288.46Cr 23Cr 22Cr 997.21Cr | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Feng Lin Hsu
BRD | Director/Board Member | 76 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -58.47% | 5.19Cr | |
| -3.94% | -2.15% | +52.66% | +155.27% | 1,07900Cr | |
| -3.57% | -1.32% | +52.96% | +52.71% | 64TCr | |
| -1.96% | +0.26% | +36.07% | +72.21% | 47TCr | |
| -2.29% | +1.12% | +36.13% | +30.60% | 35TCr | |
| -2.28% | -0.69% | +33.42% | +39.21% | 30TCr | |
| -3.15% | +0.25% | +10.63% | +13.71% | 27TCr | |
| -2.12% | +3.31% | +1.82% | -39.41% | 23TCr | |
| -1.41% | +3.03% | +27.00% | +63.46% | 21TCr | |
| -2.36% | -0.89% | +13.01% | +70.33% | 16TCr | |
| Average | -2.17% | +4.79% | +26.37% | +39.96% | 37.1TCr | |
| Weighted average by Cap. | -3.00% | +4.86% | +38.11% | +74.68% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 54Cr 1.66Cr 1.46Cr 1.36Cr 1.25Cr 2.34Cr 159.27Cr 2.4Cr 16Cr 6.32Cr 79Cr 6.24Cr 6.11Cr 272.46Cr | 51Cr 1.59Cr 1.39Cr 1.3Cr 1.2Cr 2.24Cr 152.06Cr 2.29Cr 15Cr 6.04Cr 75Cr 5.96Cr 5.83Cr 260.13Cr |
| Net income | -17Cr -53.86L -47.32L -44.17L -40.54L -75.89L -52Cr -77.76L -5.24Cr -2.05Cr -26Cr -2.02Cr -1.98Cr -88Cr | -30Cr -91.43L -80.34L -74.99L -68.82L -1.29Cr -88Cr -1.32Cr -8.89Cr -3.48Cr -43Cr -3.43Cr -3.36Cr -149.82Cr |
| Net Debt | 25Cr 76.02L 66.8L 62.36L 57.23L 1.07Cr 73Cr 1.1Cr 7.39Cr 2.89Cr 36Cr 2.85Cr 2.79Cr 124.57Cr | 29Cr 89.15L 78.34L 73.12L 67.11L 1.26Cr 85Cr 1.29Cr 8.67Cr 3.39Cr 42Cr 3.35Cr 3.27Cr 146.08Cr |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
